# Study Design Engine - Canonical Patterns v1.0
# 11 patterns with full metadata per VP CRO spec

patterns:
  - id: SAD
    version: "1.0"
    title: "Single Ascending Dose"
    allowed_pathways: [innovator]
    allowed_objectives: [pk_safety]
    summary:
      structure: sequential_cohorts
      randomization: optional
      blinding: single_blind
      arms: 2
      comparator: placebo
      key_features: ["dose escalation", "sentinel dosing optional"]
    typical_n_range:
      min: 24
      max: 48
      unit: subjects
    constraints:
      requires_interim: false
      supports_interim: false
      requires_event_driven: false
      allows_crossover: false
      allows_superiority: false
      requires_equivalence_or_ni: false
    tags: [regulatory_standard]
    rationale:
      what: "Selected design: SAD with sequential cohorts and placebo control."
      why: "This design is appropriate for first-in-human assessment of safety, tolerability, and initial PK under controlled exposure escalation."
      reg: "This aligns with standard early clinical development expectations for FIH programs."
      assumptions:
        - "Assumes no prior human safety signals requiring modified escalation."
    priority: 10
    specificity_score: 90

  - id: MAD
    version: "1.0"
    title: "Multiple Ascending Dose"
    allowed_pathways: [innovator]
    allowed_objectives: [pk_safety]
    summary:
      structure: sequential_cohorts
      randomization: optional
      blinding: single_blind
      arms: 2
      comparator: placebo
      key_features: ["repeat dosing", "accumulation assessment"]
    typical_n_range:
      min: 40
      max: 80
      unit: subjects
    constraints:
      requires_interim: false
      supports_interim: false
      requires_event_driven: false
      allows_crossover: false
      allows_superiority: false
      requires_equivalence_or_ni: false
    tags: [regulatory_standard]
    rationale:
      what: "Selected design: MAD with sequential cohorts and placebo control."
      why: "Repeated dosing supports assessment of safety and PK at steady-state and characterization of exposure-related effects."
      reg: "This aligns with standard early-phase expectations prior to dose selection."
      assumptions:
        - "Assumes dose escalation rules and stopping criteria are pre-specified."
    priority: 11
    specificity_score: 88

  - id: DOSE_RANGING_PARALLEL
    version: "1.0"
    title: "Parallel Dose-Ranging"
    allowed_pathways: [innovator]
    allowed_objectives: [dose_selection]
    summary:
      structure: parallel
      randomization: required
      blinding: double_blind
      arms: variable
      comparator: placebo_or_active
      key_features: ["dose-response", "multiple dose arms"]
    typical_n_range:
      min: 100
      max: 300
      unit: patients
    constraints:
      requires_interim: false
      supports_interim: true
      requires_event_driven: false
      allows_crossover: false
      allows_superiority: false
      requires_equivalence_or_ni: false
      min_arms: 3
      max_arms: 6
    tags: [standard_of_care]
    rationale:
      what: "Selected design: randomized, double-blind, parallel dose-ranging trial."
      why: "Parallel dose-ranging supports dose-response characterization and selection of doses for confirmatory testing."
      reg: "This is a widely accepted approach for Phase 2 dose selection across FDA and EMA programs."
      assumptions:
        - "Assumes endpoints are sensitive enough to differentiate doses within feasible sample sizes."
    priority: 20
    specificity_score: 75

  - id: ADAPTIVE_DOSE_FINDING
    version: "1.0"
    title: "Adaptive Dose-Finding"
    allowed_pathways: [innovator]
    allowed_objectives: [dose_selection]
    summary:
      structure: parallel
      randomization: required
      blinding: double_blind
      arms: variable
      comparator: placebo_or_active
      key_features: ["interim analysis", "adaptive allocation or dropping arms"]
    typical_n_range:
      min: 120
      max: 300
      unit: patients
      note: "depends on adaptive algorithm and endpoint variance"
    constraints:
      requires_interim: true
      supports_interim: true
      requires_event_driven: false
      allows_crossover: false
      allows_superiority: false
      requires_equivalence_or_ni: false
      min_arms: 3
      max_arms: 8
    tags: [adaptive]
    rationale:
      what: "Selected design: randomized, double-blind adaptive dose-finding trial with interim analysis."
      why: "Adaptive dose-finding can improve efficiency by concentrating allocation and decisions using pre-specified interim rules."
      reg: "Adaptive designs are acceptable when interim analyses and type I error control are pre-specified."
      assumptions:
        - "Assumes interim analysis plan and adaptation rules are locked before first patient in."
    priority: 25
    specificity_score: 80

  - id: SEAMLESS_PHASE_2_3
    version: "1.0"
    title: "Seamless Phase 2/3"
    allowed_pathways: [innovator]
    allowed_objectives: [dose_selection, confirmatory_efficacy]
    summary:
      structure: parallel
      randomization: required
      blinding: double_blind
      arms: variable
      comparator: placebo_or_active
      key_features: ["dose selection + confirmatory", "interim gate", "inferential continuity"]
    typical_n_range:
      min: 300
      max: 800
      unit: patients
      note: "program dependent"
    constraints:
      requires_interim: true
      supports_interim: true
      requires_event_driven: false
      allows_crossover: false
      allows_superiority: true
      requires_equivalence_or_ni: false
    tags: [seamless, adaptive]
    rationale:
      what: "Selected design: randomized, double-blind seamless Phase 2/3 trial with interim gate."
      why: "A seamless approach can combine dose selection and confirmatory assessment while maintaining pre-specified inferential controls."
      reg: "Acceptable when transition criteria, interim analysis, and multiplicity control are prospectively defined."
      assumptions:
        - "Assumes operational readiness to run a combined program without protocol fragmentation."
    priority: 40
    specificity_score: 60

  - id: CONFIRMATORY_RCT_SUPERIORITY
    version: "1.0"
    title: "Confirmatory RCT - Superiority"
    allowed_pathways: [innovator]
    allowed_objectives: [confirmatory_efficacy]
    summary:
      structure: parallel
      randomization: required
      blinding: double_blind
      arms: 2
      comparator: placebo_or_active
      key_features: ["pre-specified hypothesis", "multiplicity control as needed"]
    typical_n_range:
      min: 300
      max: 3000
      unit: patients
      note: "endpoint/event-rate dependent"
    constraints:
      requires_interim: false
      supports_interim: true
      requires_event_driven: false
      allows_crossover: false
      allows_superiority: true
      requires_equivalence_or_ni: false
    tags: [standard_of_care]
    rationale:
      what: "Selected design: randomized, double-blind, parallel-group confirmatory RCT (superiority)."
      why: "This design provides the strongest basis for causal efficacy inference under controlled bias and confounding."
      reg: "This aligns with standard confirmatory evidence expectations for FDA and EMA approvals."
      assumptions:
        - "Assumes clinically meaningful effect size and validated endpoints."
    priority: 30
    specificity_score: 70

  - id: EVENT_DRIVEN_CONFIRMATORY
    version: "1.0"
    title: "Event-Driven Confirmatory Trial"
    allowed_pathways: [innovator]
    allowed_objectives: [confirmatory_efficacy]
    summary:
      structure: parallel
      randomization: required
      blinding: double_blind
      arms: 2
      comparator: placebo_or_active
      key_features: ["time-to-event endpoint", "event-driven power", "DSMB recommended"]
    typical_n_range:
      min: 500
      max: 3000
      unit: patients
      note: "depends on event rate and follow-up"
    constraints:
      requires_interim: false
      supports_interim: true
      requires_event_driven: true
      allows_crossover: false
      allows_superiority: true
      requires_equivalence_or_ni: false
    tags: [event_driven, standard_of_care]
    rationale:
      what: "Selected design: randomized, double-blind event-driven confirmatory trial (time-to-event)."
      why: "Event-driven powering ensures adequate statistical information for time-to-event endpoints."
      reg: "This is consistent with common confirmatory standards in CV outcomes and oncology programs."
      assumptions:
        - "Assumes event definition and adjudication are pre-specified and operationalized."
    priority: 31
    specificity_score: 72

  - id: PK_CROSSOVER_BE
    version: "1.0"
    title: "2x2 Crossover Bioequivalence"
    allowed_pathways: [generic]
    allowed_objectives: [pk_equivalence]
    summary:
      structure: crossover
      randomization: required
      blinding: open_label
      arms: 2
      comparator: reference
      key_features: ["2x2 crossover", "fasting/fed as required", "90% CI for AUC/Cmax"]
    typical_n_range:
      min: 24
      max: 48
      unit: subjects
    constraints:
      requires_interim: false
      supports_interim: false
      requires_event_driven: false
      allows_crossover: true
      allows_superiority: false
      requires_equivalence_or_ni: true
    tags: [be, regulatory_standard]
    drug_characteristics:
      avoid_if:
        halfLifeHours_gte: 24
    rationale:
      what: "Selected design: randomized, open-label, 2x2 crossover BE study."
      why: "A crossover BE design is the regulatory standard to demonstrate PK equivalence between test and reference."
      reg: "This meets typical FDA ANDA expectations under 505(j) when applicable."
      assumptions:
        - "Assumes reference product is available and washout is feasible."
    priority: 5
    specificity_score: 95

  - id: PK_CROSSOVER_BE_REPLICATE
    version: "1.0"
    title: "Replicate Crossover BE (HVD-friendly)"
    allowed_pathways: [generic]
    allowed_objectives: [pk_equivalence]
    summary:
      structure: crossover
      randomization: required
      blinding: open_label
      arms: 2
      comparator: reference
      key_features: ["replicate design", "within-subject variability", "scaled BE where applicable"]
    typical_n_range:
      min: 32
      max: 60
      unit: subjects
      note: "often used when variability is high"
    constraints:
      requires_interim: false
      supports_interim: false
      requires_event_driven: false
      allows_crossover: true
      allows_superiority: false
      requires_equivalence_or_ni: true
    tags: [be, regulatory_standard]
    drug_characteristics:
      prefer_if:
        isHVD: true
    rationale:
      what: "Selected design: randomized, open-label replicate crossover BE study."
      why: "A replicate design can improve robustness for highly variable drugs by estimating within-subject variability."
      reg: "This aligns with common regulatory approaches for HVD scenarios where scaled BE may be applicable."
      assumptions:
        - "Assumes replicate design and analysis plan are pre-specified."
    priority: 6
    specificity_score: 92

  - id: PK_PARALLEL_SIMILARITY
    version: "1.0"
    title: "Comparative PK Similarity (Parallel)"
    allowed_pathways: [biosimilar]
    allowed_objectives: [pk_similarity]
    summary:
      structure: parallel
      randomization: required
      blinding: open_label
      arms: 2
      comparator: reference
      key_features: ["comparative PK", "immunogenicity monitoring"]
    typical_n_range:
      min: 150
      max: 250
      unit: subjects
    constraints:
      requires_interim: false
      supports_interim: false
      requires_event_driven: false
      allows_crossover: false
      allows_superiority: false
      requires_equivalence_or_ni: true
    tags: [biosimilar_only, regulatory_standard]
    rationale:
      what: "Selected design: randomized, open-label, parallel-group comparative PK similarity study."
      why: "Parallel comparative PK is appropriate for biologics where crossover is impractical and immunogenicity must be monitored."
      reg: "This follows biosimilar development expectations for PK similarity as part of totality of evidence."
      assumptions:
        - "Assumes reference product sourcing (US/EU) is aligned with target jurisdiction."
    priority: 7
    specificity_score: 93

  - id: CONFIRMATORY_RCT_EQUIVALENCE
    version: "1.0"
    title: "Clinical Equivalence / Non-Inferiority RCT"
    allowed_pathways: [biosimilar]
    allowed_objectives: [clinical_equivalence]
    summary:
      structure: parallel
      randomization: required
      blinding: double_blind
      arms: 2
      comparator: reference
      key_features: ["equivalence or NI margin", "sensitive endpoint", "immunogenicity assessment"]
    typical_n_range:
      min: 300
      max: 800
      unit: patients
    constraints:
      requires_interim: false
      supports_interim: true
      requires_event_driven: false
      allows_crossover: false
      allows_superiority: false
      requires_equivalence_or_ni: true
    tags: [biosimilar_only, regulatory_standard]
    rationale:
      what: "Selected design: randomized, double-blind, parallel clinical equivalence/NI trial versus reference."
      why: "Equivalence or non-inferiority designs are required to demonstrate no clinically meaningful differences versus the reference product."
      reg: "This aligns with FDA/EMA biosimilar frameworks focusing on totality of evidence, not superiority."
      assumptions:
        - "Assumes equivalence/NI margins and endpoint sensitivity are justified and pre-specified."
    priority: 12
    specificity_score: 85

  - id: OBSERVATIONAL_REGISTRY
    version: "1.0"
    title: "Observational Registry / RWE"
    allowed_pathways: [post_marketing]
    allowed_objectives: [long_term_safety, effectiveness]
    summary:
      structure: observational
      randomization: none
      blinding: none
      arms: variable
      comparator: none
      key_features: ["non-interventional", "long-term follow-up", "real-world endpoints"]
    typical_n_range:
      min: 1000
      max: 10000
      unit: patients
    constraints:
      requires_interim: false
      supports_interim: false
      requires_event_driven: false
      allows_crossover: false
      allows_superiority: false
      requires_equivalence_or_ni: false
    tags: [rwe, regulatory_standard]
    rationale:
      what: "Selected design: post-marketing observational registry (RWE)."
      why: "Observational designs support long-term safety surveillance and real-world effectiveness assessment without interventional assignment."
      reg: "This aligns with common post-authorization commitments and pharmacovigilance expectations."
      assumptions:
        - "Assumes data sources, follow-up, and confounding controls are specified."
    priority: 3
    specificity_score: 90
